Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II neoadjuvant gemcitabine/S-1 chemoradiotherapy for potentially resectable pancreatic ductal adenocarcinoma
jRCTs041200079Phase 2Recruiting
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine and tegafur in pancreatic adenocarcinoma (PDAC) (2 arms). Primary endpoint: Histological response in resected specimens. Started Jan 2021; status: recruiting.
02
Drugs
gemcitabinetegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCTs041200079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200079.